Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
Abstract Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-07-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13287-020-01804-6 |
| _version_ | 1828855279895183360 |
|---|---|
| author | Kun Xiao Fei Hou Xiuyu Huang Binbin Li Zhi Rong Qian Lixin Xie |
| author_facet | Kun Xiao Fei Hou Xiuyu Huang Binbin Li Zhi Rong Qian Lixin Xie |
| author_sort | Kun Xiao |
| collection | DOAJ |
| description | Abstract Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic. |
| first_indexed | 2024-12-13T00:51:49Z |
| format | Article |
| id | doaj.art-cb0011a1664444ab9ea220de6e2f6eba |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-13T00:51:49Z |
| publishDate | 2020-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-cb0011a1664444ab9ea220de6e2f6eba2022-12-22T00:04:55ZengBMCStem Cell Research & Therapy1757-65122020-07-011111710.1186/s13287-020-01804-6Mesenchymal stem cells: current clinical progress in ARDS and COVID-19Kun Xiao0Fei Hou1Xiuyu Huang2Binbin Li3Zhi Rong Qian4Lixin Xie5Department of Pulmonary and Critical Care Medicine, Chinese People’s Liberation Army (PLA) General HospitalDepartment of Pulmonary and Critical Care Medicine, Chinese People’s Liberation Army (PLA) General HospitalScientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityScientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityScientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen UniversityDepartment of Pulmonary and Critical Care Medicine, Chinese People’s Liberation Army (PLA) General HospitalAbstract Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic.http://link.springer.com/article/10.1186/s13287-020-01804-6Acute respiratory distress syndromeCell therapyMesenchymal stem cellsCOVID-19Clinical trials |
| spellingShingle | Kun Xiao Fei Hou Xiuyu Huang Binbin Li Zhi Rong Qian Lixin Xie Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Stem Cell Research & Therapy Acute respiratory distress syndrome Cell therapy Mesenchymal stem cells COVID-19 Clinical trials |
| title | Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |
| title_full | Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |
| title_fullStr | Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |
| title_full_unstemmed | Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |
| title_short | Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |
| title_sort | mesenchymal stem cells current clinical progress in ards and covid 19 |
| topic | Acute respiratory distress syndrome Cell therapy Mesenchymal stem cells COVID-19 Clinical trials |
| url | http://link.springer.com/article/10.1186/s13287-020-01804-6 |
| work_keys_str_mv | AT kunxiao mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 AT feihou mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 AT xiuyuhuang mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 AT binbinli mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 AT zhirongqian mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 AT lixinxie mesenchymalstemcellscurrentclinicalprogressinardsandcovid19 |